Real-world clinical impact of first-line immune checkpoint inhibitor-based therapy in advanced esophageal squamous cell carcinoma

Background: Chemotherapy (chemo) combined with an immune checkpoint inhibitor (ICI) or dual ICI therapy with nivolumab and ipilimumab (nivo + ipi) is the standard first-line treatment for patients with advanced esophageal squamous cell carcinoma (ESCC). In this study, we evaluated real-world clinica...

Πλήρης περιγραφή

Λεπτομέρειες βιβλιογραφικής εγγραφής

Κύριοι συγγραφείς:	M. Tamba, K. Chin, H. Osumi, M. Ogura, S. Fukuoka, S. Udagawa, K. Shimozaki, K. Yoshino, T. Wakatsuki, E. Shinozaki, K. Yamaguchi, A. Ooki
Μορφή:	Artigo
Γλώσσα:	Inglês
Έκδοση:	Elsevier 2025-06-01
Σειρά:	ESMO Gastrointestinal Oncology
Θέματα:	esophageal cancer esophageal squamous cell carcinoma chemotherapy immunotherapy early tumor shrinkage depth of response
Διαθέσιμο Online:	http://www.sciencedirect.com/science/article/pii/S2949819825000408
Ετικέτες:	Προσθήκη ετικέτας Δεν υπάρχουν, Καταχωρήστε ετικέτα πρώτοι!